CPR Investments Inc. Grows Stock Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI)

CPR Investments Inc. increased its holdings in Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 80.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 101,000 shares of the company’s stock after acquiring an additional 45,000 shares during the period. CPR Investments Inc. owned approximately 0.77% of Calidi Biotherapeutics worth $116,000 at the end of the most recent quarter.

Separately, Delta Investment Management LLC raised its stake in shares of Calidi Biotherapeutics by 1,955.0% in the 2nd quarter. Delta Investment Management LLC now owns 210,230 shares of the company’s stock valued at $42,000 after acquiring an additional 200,000 shares during the period. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Price Performance

NYSE:CLDI opened at $0.89 on Wednesday. The business’s 50 day moving average is $1.73. Calidi Biotherapeutics, Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $16.80.

Calidi Biotherapeutics (NYSE:CLDI) last issued its earnings results on Tuesday, November 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.20. As a group, equities analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 EPS for the current year.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.